Key result
Treatment of diabetic infarcted myocardium with FGF-9 significantly reduced adverse cardiac remodeling to 11.59% compared to 33% in the MI group.
Why the study?
Does FGF-9 improve cardiac remodeling and function in diabetic mice post-myocardial infarction?
Does FGF-9 improve cardiac remodeling and function in diabetic mice post-myocardial infarction?
FGF-9 demonstrates therapeutic potential in mitigating adverse cardiac remodeling and improving function in the post-MI diabetic heart by promoting M2 macrophage differentiation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for FGF-9 in diabetic post-MI remodeling; leaves open clinical translation.
Inflammation has been implicated as a perpetrator of diabetes and its associated complications. Monocytes, key mediators of inflammation, differentiate into pro-inflammatory M1 macrophages and anti-inflammatory M2 macrophages upon infiltration of damaged tissue. However, the inflammatory cell types, which propagate diabetes progression and consequential adverse disorders, remain unclear. The current study was undertaken to assess monocyte infiltration and the role of fibroblast growth factor-9 (FGF-9) on monocyte to macrophage differentiation and cardioprotection in the diabetic infarcted heart. Db/db diabetic mice were assigned to sham, myocardial infarction (MI), and MI+FGF-9 groups. MI was induced by permanent coronary artery ligation and animals were subjected to 2D transthoracic echocardiography two weeks post-surgery. Immunohistochemical and immunoassay results from heart samples collected suggest significantly increased infiltration of monocytes (Mean ± SEM; MI: 2.02% ± 0.23% vs. Sham 0.75% ± 0.07%; p<0.05) and associated pro-inflammatory cytokines (TNF-α, MCP-1, and IL-6), adverse cardiac remodeling (Mean ± SEM; MI: 33% ± 3.04% vs. Sham 2.2% ± 0.33%; p<0.05), and left ventricular dysfunction (Mean ± SEM; MI: 35.4% ± 1.25% vs. Sham 49.19% ± 1.07%; p<0.05) in the MI group. Importantly, treatment of diabetic infarcted myocardium with FGF-9 resulted in significantly decreased monocyte infiltration (Mean ± SEM; MI+FGF-9: 1.39% ± 0.1% vs. MI: 2.02% ± 0.23%; p<0.05), increased M2 macrophage differentiation (Mean ± SEM; MI+FGF-9: 4.82% ± 0.86% vs. MI: 0.85% ± 0.3%; p<0.05) and associated anti-inflammatory cytokines (IL-10 and IL-1RA), reduced adverse remodeling (Mean ± SEM; MI+FGF-9: 11.59% ± 1.2% vs. MI: 33% ± 3.04%; p<0.05), and improved cardiac function (Fractional shortening, Mean ± SEM; MI+FGF-9: 41.51% ± 1.68% vs. MI: 35.4% ± 1.25%; p<0.05). In conclusion, our data suggest FGF-9 possesses novel therapeutic potential in its ability to mediate monocyte to M2 differentiation and confer cardiac protection in the post-MI diabetic heart.
No takes yet. Share an insight, caveat, or question.
Singla et al. (2015) studied Myocardial infarction in diabetes. Fibroblast Growth Factor-9 (FGF-9) vs. Myocardial infarction without FGF-9 was evaluated on Adverse cardiac remodeling (p=<0.05). Treatment of diabetic infarcted myocardium with FGF-9 significantly reduced adverse cardiac remodeling to 11.59% compared to 33% in the MI group.
Synapse has enriched 10 related papers. Consider them for comparative context: